市場調査レポート

商品コード

1454157

標的治療薬の世界市場：市場規模、シェア、成長分析 - タイプ別、用途別、産業予測（2024～2031年）

Global Targeted Therapeutics Market Size, Share, Growth Analysis, By Type(Monoclonal Antibodies and Small Molecule), By Application(Breast Cancer, Colorectal Cancer) - Industry Forecast 2024-2031

出版日: 2024年03月09日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 792,986円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 927,644円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,062,302円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.62円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界の標的治療薬の市場規模は、2022年に705億7,000万米ドルに達し、2024～2031年の予測期間中にCAGR 2.10%で成長し、2023年の720億5,000万米ドルから2031年には850億8,000万米ドルに達すると予測されています。

同市場は、生物製剤の人気上昇と拡大により急成長を遂げています。さらに、バイオテクノロジー分野への投資が活発化していることも、世界市場の拡大に寄与しています。モノクローナル抗体は、生物製剤産業の目覚ましい成長と進歩の結果、最も求められている治療法の1つに浮上しました。これらの標的治療薬は、腫瘍細胞の増殖を効果的に阻止する上で極めて重要な役割を果たしています。今後数年間は、オンライン薬局の普及が特定の治療薬の販売を促進すると予想されます。業界の成長を左右するもう1つの重要な要因は、世界の標的治療薬市場全体で、高度なヘルスケアインフラの整備に対する政府支出が急増していることです。2040年までに、世界中で推定2,840万件の症例が予測されています。さらに、標的治療薬の利用可能性に関する国民の意識の高まりが、世界市場の拡大を後押ししています。しかし、標的治療薬や薬剤に伴う副作用が市場成長の妨げになると予想されます。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と見通し

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

世界の標的治療薬市場：タイプ別

市場概要
モノクローナル抗体と低分子化合物

世界の標的治療薬市場：用途別

市場概要
乳がん
大腸がん
肺がん
腎臓がん

世界の標的治療薬市場：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

Roche Holding AG
Novartis AG
Amgen Inc.
AstraZeneca Plc
Merck & Co. Inc.
Pfizer Inc.
Eli Lilly and Company
Bayer AG
Bristol-Myers Squibb Company
GlaxoSmithKline Plc
AbbVie Inc.
Biogen Inc.
Sanofi S.A.
Johnson & Johnson
Takeda Pharmaceutical Co. Ltd.
Gilead Sciences Inc.
Vertex Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Celgene Corporation（a subsidiary of Bristol-Myers Squibb Company）
Regeneron Pharmaceuticals Inc.

Product Code: SQMIG35H2052

Global Targeted Therapeutics Market size was valued at USD 70.57 billion in 2022 and is poised to grow from USD 72.05 billion in 2023 to USD 85.08 billion by 2031, growing at a CAGR of 2.10% during the forecast period (2024-2031).

The market has experienced rapid growth attributed to the increasing popularity and expansion of biologics. Furthermore, the global market is witnessing expansion due to heightened investments in the biotechnology sector. Monoclonal antibodies have emerged as one of the most sought-after treatments resulting from the remarkable growth and advancement in the biologics industry. These targeted therapeutics play a pivotal role in halting the proliferation of tumor cells effectively. Over the forthcoming years, the proliferation of online pharmacies is expected to drive sales of specific therapeutic drugs. Another significant factor poised to influence the industry's growth is the escalating government expenditure on developing advanced healthcare infrastructure across the global targeted therapeutics market. By 2040, an estimated 28.4 million cases are projected worldwide. Moreover, increasing awareness among the population regarding the availability of targeted therapeutics is propelling the expansion of the global market. However, the market growth is expected to be hindered by the side effects associated with targeted therapies and drugs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Therapeutics Market Segmental Analysis

Global targeted therapeutics market is segmented based on type, application, and region. By type, the market is segmented into Monoclonal antibodies and small molecule. By application, the market is segmented into Breast cancer, colorectal cancer, lung cancer, and renal cancer. By region the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA.

Drivers of the Global Targeted Therapeutics Market

The widespread prevalence of cancer serves as the main catalyst for the growth of the targeted therapeutics market. The rising number of smokers contributes significantly to this trend, as smoking is identified as the leading cause of cancer-related deaths globally. In 2021, an estimated 235,760 individuals in the United States alone are expected to receive a lung cancer diagnosis, with approximately 130,000 deaths attributed to lung cancer annually in the country. Moreover, the global increase in smoking prevalence, which has surged by over 19%, underscores that this issue extends beyond the borders of the United States.

Restraints in the Global Targeted Therapeutics Market

Targeted therapies and their corresponding medications play a crucial role in cancer treatment across various applications. Nevertheless, significant health concerns accompany such treatments, posing a potential obstacle to market growth. Common risks associated with targeted therapy include hepatitis, diarrhea, and liver issues like elevated liver enzymes. Additionally, individuals undergoing targeted therapy may experience adverse effects such as hair loss, skin rashes, reduced sperm production, and hypertension.

Market Trends of the Global Targeted Therapeutics Market

Key players in the global therapeutics market are actively engaged in collaboration agreements, acquisitions, and new product launches, all of which are anticipated to drive market growth. Several competitors in this market have implemented expansion strategies to enhance their market presence. For instance, PubMed Inc. has introduced upgraded versions of complement-targeted therapies designed to address various disease and pathological conditions, thereby boosting the sales of complement-targeted therapies.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Targeted Therapeutics Market by Type

Market Overview
Monoclonal Antibodies and Small Molecule

Global Targeted Therapeutics Market by Application

Market Overview
Breast Cancer
Colorectal Cancer
Lung Cancer
Renal Cancer

Global Targeted Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments